Home Featured 2

Featured 2

Featured posts

Most popular

Adjuvant EGFR-TKI for Resected NSCLC: Who, When, and Where?

lungcanc

Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC

Understanding the Effects of Time to Surgery on Upstaging for Stage I Non-Small Cell Lung Cancer

Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia

Ireland’s Complex Healthcare System and Its Relation to Innovative Ways for Patients to Access Trials

Expanding Efforts Help Address Disparities in Lung Cancer Care

lungcanc

Ongoing Clinical Challenges: Defining Immunotherapy Benefit for Patients With NSCLC and...

lungcanc

SHAWL: Largest Study of Its Kind Evaluates Sexual Dysfunction in Women...

lungcanc

ICU Care for the Patient with Lung Cancer

lungcanc

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: A Q&A With Dr....

lungcanc

$Tackling TKI-Refractory Disease in Patients with Oncogenic Drivers: An Interview with Dr. Mark Socinski$

Tackling TKI-Refractory Disease in Patients with Oncogenic Drivers: An Interview with...

lungcanc

Broad Molecular Testing in Lung Cancer: The Struggle to Translate Recommendations...

lungcanc

Nuances of PET Interpretation in Thoracic Oncology: More Than Just Lung...

lungcanc

Rebuilding Choice Architecture for Incurable but Treatable Lung Cancer: Rethinking the...

lungcanc

Brain Metastases in NSCLC: Is Delaying Upfront Radiation a Viable Option?

lungcanc

12 3...7 Page 1 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib